Patent · US Active

1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors

US10106515B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignee

GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

Weichun Chen · Zhejiang, CN
Ebere F Igboko · Shanghai, CN
Xichen Lin · Shanghai, CN
Hongfu Lu · Shanghai, CN
Feng Ren · Shanghai, CN
Paul Bryan Wren · Uxbridge, GB
Zhongmiao Xu · Shanghai, CN
Ting Yang · Shanghai, CN
Lingdong Zhu · Shanghai, CN

Key dates

Filing date	May 27, 2015
Grant date	Oct 23, 2018
Priority date	—
Expiry date	May 27, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.